pCODR

Prostate Cancer Canada (PCC) is a proud patient group member of the pan-Canadian Oncology Drug Review (pCODR). pCODR was established by Canada's provincial and territorial Ministries of Health (with the exception of Quebec) to assess cancer drug therapies and make recommendations to guide drug-funding decisions. PCC participates in this process by collecting feedback from patients and caregivers and submitting this feedback to pCODR.

To learn more about pCODR please visit their website.


Current Drugs Under Review


No drugs are being reviewed at this time.


If you have any questions, please contact drugcoverage@prostatecancer.ca 

Donate Now!






Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive